Evaxion Biotech A/S (EVAX) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.53
↓-60% vs avg
5yr avg: 3.81
30Y Low1.8·High6.3
ROE
↑
-100.5%
↓+75% vs avg
5yr avg: -394.2%
30Y Low-266%·High-100%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EVAX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Evaxion Biotech A/S currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $26M | $31M | $5M | $23M | $52M | $108M | — | — | — |
| Enterprise Value | $10M | $15M | $10M | $29M | $50M | $79M | — | — | — |
| P/E Ratio → | -3.36 | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.40 | 4.05 | 1.36 | 320.91 | — | — | — | — | — |
| P/B Ratio | 1.53 | 1.79 | — | — | 6.32 | 3.32 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EVAX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.96 | 2.87 | 393.34 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
EVAX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Evaxion Biotech A/S earns an operating margin of -122.7%. Operating margins have expanded from -30406.8% to -122.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -100.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.7% | 99.7% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -122.7% | -122.7% | -440.6% | -30406.8% | — | — | — | — | — |
| Net Profit Margin | -102.4% | -102.4% | -316.0% | -30308.2% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -100.5% | -100.5% | — | -1238.1% | -113.7% | -124.3% | -183.1% | -265.5% | — |
| ROA | -37.8% | -37.8% | -83.3% | -126.7% | -74.5% | -94.1% | -130.3% | -114.2% | -65.0% |
| ROIC | -295.2% | -295.2% | -558.7% | -561.3% | -406.0% | -747.4% | -2337.9% | -11916.9% | -1388.2% |
| ROCE | -57.4% | -57.4% | -211.6% | -184.5% | -93.4% | -120.5% | -202.0% | -268.7% | — |
EVAX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $23M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.44 | — | — | 1.24 | 0.11 | 0.00 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.92 | — | — | -0.35 | -0.88 | -0.83 | -1.02 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.54 | -10.54 | -10.80 | -24.55 | -15.35 | -26.83 | -74.30 | -9.80 | -8.95 |
Net cash position: cash ($23M) exceeds total debt ($8M)
EVAX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Evaxion Biotech A/S's current ratio of 5.85x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.18x to 5.85x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.85 | 5.85 | 2.01 | 1.18 | 4.51 | 8.03 | 2.22 | 6.36 | 0.89 |
| Quick Ratio | 5.85 | 5.85 | 2.01 | 1.18 | 4.51 | 8.03 | 2.22 | 6.36 | 1.03 |
| Cash Ratio | 5.46 | 5.46 | 1.16 | 0.79 | 3.50 | 7.44 | 1.18 | 5.55 | 0.79 |
| Asset Turnover | — | 0.27 | 0.27 | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 50.80 | 202.80 | — | — | — | — | — | — |
EVAX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Evaxion Biotech A/S does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $6M | $1M | $683395 | $590967 | $487328 | $404966 | $404966 | $479966 |
Peer Comparison
Compare EVAX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EVAXYou | $26M | -3.4 | — | — | 99.7% | -122.7% | -100.5% | -295.2% | — |
 NEON | $31M | 3.6 | — | — | 98.7% | -391.5% | 41.3% | -4604.4% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 GILD | $166B | 19.8 | 17.0 | 17.6 | 86.7% | 40.1% | 40.7% | 23.4% | 2.3 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 MRNA | $19B | -6.7 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
 BNTX | $24B | -17.6 | — | 74.2 | 77.6% | -22.6% | -5.7% | -4.3% | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See EVAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVAX vs NEON
Side-by-side business, growth, and profitability comparison vs Neonode Inc..
Start ComparisonEVAX — Frequently Asked Questions
Quick answers to the most common questions about buying EVAX stock.
What is Evaxion Biotech A/S's P/E ratio?
Evaxion Biotech A/S's current P/E ratio is -3.4x. This places it at the 50th percentile of its historical range.
What is Evaxion Biotech A/S's ROE?
Evaxion Biotech A/S's return on equity (ROE) is -100.5%. The historical average is -157.4%.
Is EVAX stock overvalued?
Based on historical data, Evaxion Biotech A/S is trading at a P/E of -3.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Evaxion Biotech A/S's profit margins?
Evaxion Biotech A/S has 99.7% gross margin and -122.7% operating margin.